Gerry Wright, McMaster University – Bad Bugs, Good Bugs. What’s the Difference?

Lutz Tautz, Burnham Institute for Medical Research – Novel Tyrosine Phosphatase Inhibitors for Treatment of Yersinia Infections

Michael Pirrung, University of California, Riverside – Smallpox as a novel drug target

Daniel H. Rich, University of Wisconsin at Madison – Rational Drug Design. Where it has been and where might it go in the 21st Century

 Monday, February 27, 2006

 Recent Advances in Organic Chemistry Methodology
Organized by Emory University Chemistry Department

Morning Session            8:00 AM – 11:00 AM
Albert Padwa, Emory University, Program Chair 

Lanny Liebeskind, Emory University – Metals, Methods, and Molecules              

Frank McDonald, Emory University – Biomimetic Synthesis via Polyepoxide Cyclizations

Justin Gallivan, Emory University – Genetic Screens and Selections for Small Molecules
         
Stefan Lutz , Emory University – Tailoring Biocatalysts for Enantioselective  Synthesis
           
Dennis Liotta, Emory University – New  Therapies for Treating Viral Diseases and Cancers

General Oral Papers
Afternoon Session    1:00 PM – 4:00 PM
John Dodd, Bristol-Myers Squibb, Program Chair

Robert Fecik, University of Minnesota – Synthesis and Evaluation of Thioesterase Affinity Labels

Courtney Aldrich, University of Minnesota - Rationally Designed Antibiotics That Inhibit Siderophore Biosynthesis of Mycobacterium tuberculosis

Apurba Dutta, The University of Kansas - Stereoselective Routes to Bioactive Heterocycles: An Amino Acid Chiral Template Approach

Thomas Rϋckle, Serono Pharmaceutical Research Institute - Furan-2-glmethylene-Azolidine-Diones as novel, potent and selective inhibitors of Phosphoinositide 3-Kinase g.

Scott D. Edmondson, Merck and Company, Inc. - Discovery of a potent, orally active Phenylalanine Derived Dipeptidyl Peptidase IV Inhibitor for the treatment of Type 2 Diabetes

 Monday Evening Poster Session
5:30 PM – 7:30 PM
Jack Hodges, Berry and Associates, Program Chair

Tuesday, February 28, 2006

 Characterizing Bioactive Molecules in Drug Discovery
Sponsored by Genentech, Inc.

Morning Session        8:00 AM – 11:00 AM
Katerina Leftheris, Bristol-Myers Squibb, Program Chair

Donna Dambach, Bristol-Myers Squibb – Uses of Toxicogenomic Profiling in Drug Discovery

Steve Hall, Serenex – Chemoproteomics -Driven Drug Discovery:  Identification of Orally Active Hsp90 Inhibitors

Michael Reily, Pfizer Global R & D – Metabonomics in Drug Safety Assessment

Emanuel Petricoin, George Mason University – Toxicoproteomics, Early detection of Drug-Induced Toxicities

Bioactive Marine Natural Products
Evening Session     4:00 PM – 7:00 PM
Lester A. Mitscher, University of Kansas and Victor Snieckus, Queen’s University, Program Co-Chairs

Ian Paterson, University of Cambridge – Synthesis of Marine Polyketides as Promising Anticancer Agents

Robert M. Williams, Colorado State University – Total Synthesis of Biomedically Significant Nitrogenous Substances

David J. Newman, National Cancer Institute – Marine Natural Products: Novel Structures in Search of Syntheses

 Wednesday, March 1, 2006

             Young Investigators in Organic Synthesis
Morning Session    8:00 AM – 11:00 AM
Michael VanNieuwenhze, University of California, San Diego, Program Chair  

Michael VanNieuwenhze, University of California, San Diego – Synthesis and Study of Cyclic Depsipeptides that Inhibit Bacterial Cell Wall Biosynthesis

Dirk Trauner, University of California, Berkeley – Development of Photoactivated Glutamate Receptors and Other Studies in Total Synthesis 

Melanie Sanford, University of Michigan – Synthetic Applications and Mechanistic Investigations of Directed C–H Bond Oxidation 

Helen E. Blackwell, University of Wisconsin, Madison – Modulation of Bacterial Communication Pathways with Synthetic Ligands